ArticleInternational journal of women's health2025
The Efficacy and Safety of Electroacupuncture for Prophylaxis of Menstrually Related Migraine: Study Protocol for a Pilot Randomized Controlled Trial.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07023926 (The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy and Safety of Acupuncture for Prophylaxis of Menstrually Related Migraine: a Pilot Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acupuncture, a well-established non-pharmacological intervention, has displayed promise in migraine management, but high-quality evidence for its effectiveness in menstrually related migraine (MRM) prophylaxis remains scarce. This pilot randomized controlled trial will evaluate the feasibility, efficacy, and safety of electroacupuncture (EA) for MRM prevention and provide evidence-based support for future large-scale trials. Methods/Design: This single-center, participant- and assessor-blinded, sham-controlled pilot trial will assign 40 eligible patients with MRM in a 1:1 ratio to the EA or sham EA (SEA) group via block randomization. Participants will begin treatment on day -3 of each menstrual cycle (estimated according to the previous cycle), receiving 1-2 sessions during the first week (from day -3 to +4 of menstruation) and 2-3 sessions per week for the following 3 weeks. The intervention period will last 12 weeks and total 30 sessions, followed by 12 weeks of follow-up. The primary outcome is the change from baseline in standardized monthly headache days (SMHDs) at week 12. Secondary outcomes include the MRM cure rate, responder rate for MRM (≥50% reduction in SMHDs), changes in headache severity and medication use, quality of life (Migraine-Specific Quality of Life Questionnaire v2.1), psychological status (Hospital Anxiety and Depression Scale), headache-related disability (Headache Impact Test-6), global impression of change (Patient's Global Impression of Change), and feasibility measures. All analyses will follow the intention-to-treat principle with two-sided Discussion: As the first sham-controlled RCT specifically targeting MRM, this study will apply a menstrual cycle-tailored EA protocol and use uniformly assessed SMHDs as the primary outcome to enhance methodological rigor and novelty. The findings are expected to provide preliminary evidence and inform the design of future large-scale trials. Trial Registration: The trial protocol has been registered at ClinicalTrials.gov (NCT07023926).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.